Benitec Biopharma (NASDAQ: BNTC)
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-19 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.400 | ||||||
REV | 48.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Benitec Biopharma (NASDAQ: BNTC) through any online brokerage.
Other companies in Benitec Biopharma’s space includes: PolarityTE (NASDAQ:PTE), Exicure (NASDAQ:XCUR), Histogen (NASDAQ:HSTO), Brickell Biotech (NASDAQ:BBI) and Creative Medical Tech (NASDAQ:CELZ).
The latest price target for Benitec Biopharma (NASDAQ: BNTC) was reported by HC Wainwright & Co. on Thursday, February 17, 2022. The analyst firm set a price target for 10.00 expecting BNTC to rise to within 12 months (a possible 1097.60% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Benitec Biopharma (NASDAQ: BNTC) is $0.835 last updated August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for Benitec Biopharma.
Benitec Biopharma’s Q4 earnings are confirmed for Monday, September 19, 2022.
There is no upcoming split for Benitec Biopharma.
Benitec Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.